PRPH ProPhase Labs Inc

ProPhase Labs to Present at The ThinkEquity Conference

ProPhase Labs to Present at The ThinkEquity Conference

GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.

ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus will be presenting at 11:30 AM ET on October 19th. Interested parties can register to attend here:

One-on-one investor meetings will be held throughout the day.

The presentation will also be live-streamed at the following link:

About ProPhase Labs

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics, therapeutics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies and significant growth underscore our multi-billion-dollar potential.

For more information, visit .

Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.

267-880-1111

Retail Investor Relations Contact:

Renmark Financial Communications

John Boidman

514-939-3989



EN
12/10/2023

Underlying

PRPHProPhase Labs Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadsh...

ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025 Company cancels the Equity Line of Credit (ELOC) UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be participating in Renmark Financial Communications Inc’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, September 4, 2025, at 12:00 pm EDT. ProPhase Labs Inc. welcomes st...

September 3, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Announces Filing of Definitive Proxy Statement and New D...

ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) with the U.S. Securities and Exchange Commission (“SEC”) on Friday, August 15, 2025 and received a “no further comments” letter from the SEC’s Division of Corporation Finance Office of Life Sciences, indicating that the Staff had co...

August 19, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Announces Financial Results for the Three and Six Months...

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a diversified diagnostics,...

August 13, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Paten...

ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart™ test validation (>95% technical success) and, together with BE-Smart’s demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (the “Company” or “ProPh...

August 12, 2025 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on...

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025 UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch